— Silicium G7® · Clinical-Premium · Original formula
Forty-four years under the microscope.
Seventy published clinical studies across twelve international centers validate Dr. Loïc Le Ribault’s original formula. This is what science has shown — no headlines, no shortcuts.
Novel Food 2016
Reg. 2017/2470
471 · 473 · 474
NOAEL 2,000 mg/kg
Oiartzun, Gipuzkoa
How do we know it works?
Because it has been measured. Not by us — but by twelve independent scientific centers over four decades, with published, peer-reviewed trials. Here is the short version. We keep the full version for the professionals who request it.
Five milestones that marked the way.
Edith Carlisle shows that silicon is essential for bone formation. A science is born.
Dr. Loïc Le Ribault synthesizes the first stable organic form. A category is born.
A double-blind trial confirms improvement in femoral bone density in postmenopausal women.
The European Union authorizes the active ingredient as a Novel Food under Regulation 2017/2470.
Documents +157 % urinary elimination of aluminum in women.
Four effects. Four figures.
Each figure corresponds to a published, reviewed clinical trial. International centers, real subjects, calibrated metrics.
Twelve centers, one single formula.
We do not fund headlines — we pay for rigor. Each study starts in a laboratory with its own audit and is published in its name, not ours.
The only organic silicon authorized by EFSA as a Novel Food.
There is an important difference between "not prohibited" and "evaluated for years and approved." In 2016, the European Food Safety Authority authorized the active ingredient under EU Regulation 2017/2470. It is the most demanding regulatory endorsement that exists in Europe for a natural supplement.
EFSA
Novel Food 2016
Full scientific assessment by the European Food Safety Authority. EU Regulation 2017/2470.
NOAEL
2,000 mg/kg
Three OECD batteries under Good Laboratory Practice: Ames (471), chromosomal aberrations (473), and micronuclei (474). Negative results.
23 years
0 adverse events
More than one and a half million units sold in Europe. Zero serious adverse events documented.
Science is not claimed.
It is proven.
The full library, upon request.
If you need the protocols, DOIs, or raw data for a clinical consultation or an article, write to us. You will receive the full documentation in less than five business days.
Please state your professional affiliation and the specific studies you need. We respond in less than 5 business days.
About the clinical studies, clear answers.
Six common questions with verifiable answers and sources.
A mix, and we label them case by case. The foundational work on silicon (Carlisle 1981, Reffitt 2003, Exley 2006–2017, Spector 2008) is completely independent: funded by public universities and research councils. The studies commissioned by Silicium —CTNS-Eurecat 2014, Mérieux 2012, UCAM 2025, AINIA 2025— are published in the name of the auditing center with its own methodology, not ours. That is the difference between sponsoring and paying for a headline.
Yes, and five are placebo-controlled double-blind: Spector 2008 (femoral bone density in postmenopausal women, King’s College London), Polonini 2018 (skin, hair, and nails), Wickett 2007 (skin collagen), Lassus 1993 (hair), and the internal prospective pharmacovigilance cohort 2023–2025. The rest are open trials or observational studies with calibrated cohorts.
More than 3,500 subjects over four decades. The pivotal studies are limited in scope (between 30 and 200 subjects each, typical for supplementation clinical trials), but the convergence across cohorts —French, Spanish, British, Brazilian— on different endpoints strengthens the signal.
The strongest data come precisely from adult and postmenopausal women: Spector 2008 documents +1.2 % femoral bone density in 12 months in that cohort; Polonini 2018 worked with adult women; Crescenti UCAM 2025 (aluminum excretion) measured both men and women. The downward slope of endogenous silicon begins at age 30 and becomes more pronounced during menopause — that is exactly when exogenous intake makes the biggest difference.
The EFSA Novel Food 2016 authorization (EU Regulation 2017/2470). It is the most demanding regulatory endorsement that exists in Europe for a natural supplement: it involves exhaustive review of safety, efficacy, and documentary traceability by the European Food Safety Authority. Added to this is NOAEL 2,000 mg/kg/d (OECD GLP) and the INCI cosmetic listing Silanetriol.
The papers with DOI are publicly accessible (you can search for them directly in PubMed or Google Scholar by author and year). The commissioned reports —CTNS-Eurecat, AINIA, UCAM, internal pharmacovigilance— are provided upon request to healthcare professionals and specialist press with prior identification. Write to us at help@silicium.com stating your affiliation and the studies you need.
The team that backs this page.
The content is signed by those who write it and those who review it. Here are the two.
Dr. Maria del Mar Sabaté Martínez
PhD in Biochemistry · Degree in Biochemistry and Chemistry · Researcher · Universitat Rovira i Virgili · Department of Basic Medical Sciences.
Juan Carlos Hierro
Founder and Director · Silicium Laboratories. Curator of the Silicium G7® scientific library. He began distributing Dr. Loïc Le Ribault’s organic silicon in 2003. Silicium is the only industrial heir to the original formula. Own GMP plant in Oiartzun, Gipuzkoa.
More science, other angles.
Forty-four years of evidence support every drop.
Dr. Le Ribault’s original formula, made in Europe and audited by EFSA. The same formula, perfected over 23 years in Gipuzkoa.